Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial
Abstract Background Mucopolysaccharidosis (MPS) Type I (MPSI) is caused by mutations in the gene encoding the lysosomal enzyme, α-L-iduronidase (IDUA), and a majority of patients present with severe neurodegeneration and cognitive impairment. Recombinant IDUA does not cross the blood-brain barrier (...
Main Authors: | Roberto Giugliani, Luciana Giugliani, Fabiano de Oliveira Poswar, Karina Carvalho Donis, Amauri Dalla Corte, Mathias Schmidt, Ruben J. Boado, Igor Nestrasil, Carol Nguyen, Steven Chen, William M. Pardridge |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-018-0849-8 |
Similar Items
-
Long-term reestablishment of alpha-L-iduronidase activity in MPS I fibroblasts after non-viral gene transfer
by: Fabiano de Oliveira Poswar, et al.
Published: (2017-12-01) -
Long-term reestablishment of alpha-L-iduronidase activity in MPS I fibroblasts after non-viral gene transfer
by: Fabiano de Oliveira Poswar, et al.
Published: (2017-12-01) -
Three novel α-L-iduronidase mutations in 10 unrelated Chinese mucopolysaccharidosis type I families
by: Luning Sun, et al.
Published: (2011-01-01) -
Three novel α-L-iduronidase mutations in 10 unrelated Chinese mucopolysaccharidosis type I families
by: Luning Sun, et al.
Published: (2011-01-01) -
Mucopolysaccharidosis type I Hurler-Scheie syndrome: A rare case report
by: Ramesh Tatapudi, et al.
Published: (2011-01-01)